How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

in-licensing antibody opportunities in oncology and fibrosis

Organization name

London BioScience Innovation Centre

Profile

Northern Biologics is a well-capitalized Canadian pharmaceutical company. The company is scouting for in-licensing opportunities in the oncology and fibrosis area, and is specifically looking for preclinical monoclonal antibodies (mAbs). The specific criteria is:

  • Oncology
    • All tumor types
    • Interested in primary tumor regression only – not reduction of metastases etc
    • mAbs targeting the tumor microenvironment (especially stroma, CAFs, etc) are of very high interest
    • mAbs requiring combinations with existing agents are still of interest
  • Fibrosis
    • Lung (IPF) and renal fibrosis are of highest interest
    • Liver, myelofibrosis, scleroderma also of interest
  • Stage
    • Of most interest for is in vivo efficacy with a final candidate – little to no optimization required (e.g. affinity maturation, humanization)
    • Also need to see data that mAb has been scaled up with few developability liabilities
  • Differentiation
    • The more differentiated the better
    • Novel targets and mAbs are of very high interest – the company is very willing to take risks on novel biology
    • Known/validated targets are acceptable, unless there are already several clinical competitors
    • Naked antibodies with known/validated formats are best
    • Alternative scaffolds and formats (e.g. bispecifics) are acceptable, as long as the scaffold has been used in humans
    • ADC are of interest only if cynomolgus tox data is available

Please direct your interest to:

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries